TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04595227

Intervention type: DEVICE
Intervention: Computerized pupillary light reflex assessment device
Description: CPLRAD may serve as an effective screening tool for glaucomatous optic neuropathy, since they can dynamically detect abnormal pupillary responses from a novel sequence of light stimuli and functionally-shaped stimuli. CPLRAD can collect the clinical examination data and objectively measure the pupil dynamic parameters monocularly and/or binocularly as indicators from the retina and optic nerve in glaucoma patients.

Intervention type: DEVICE
Intervention: Computerized pupillary light reflex assessment device
Description: CPLRAD may serve as an effective screening tool for glaucomatous optic neuropathy, since they can dynamically detect abnormal pupillary responses from a novel sequence of light stimuli and functionally-shaped stimuli. CPLRAD can collect the clinical examination data and objectively measure the pupil dynamic parameters monocularly and/or binocularly as indicators from the retina and optic nerve in glaucoma patients.

Intervention type: DEVICE
Intervention: Computerized pupillary light reflex assessment device
Description: CPLRAD may serve as an effective screening tool for glaucomatous optic neuropathy, since they can dynamically detect abnormal pupillary responses from a novel sequence of light stimuli and functionally-shaped stimuli. CPLRAD can collect the clinical examination data and objectively measure the pupil dynamic parameters monocularly and/or binocularly as indicators from the retina and optic nerve in glaucoma patients.

Intervention type: DEVICE
Intervention: Computerized pupillary light reflex assessment device
Description: CPLRAD may serve as an effective screening tool for glaucomatous optic neuropathy, since they can dynamically detect abnormal pupillary responses from a novel sequence of light stimuli and functionally-shaped stimuli. CPLRAD can collect the clinical examination data and objectively measure the pupil dynamic parameters monocularly and/or binocularly as indicators from the retina and optic nerve in glaucoma patients.

Intervention type: DEVICE
Intervention: Computerized pupillary light reflex assessment device
Description: CPLRAD may serve as an effective screening tool for glaucomatous optic neuropathy, since they can dynamically detect abnormal pupillary responses from a novel sequence of light stimuli and functionally-shaped stimuli. CPLRAD can collect the clinical examination data and objectively measure the pupil dynamic parameters monocularly and/or binocularly as indicators from the retina and optic nerve in glaucoma patients.
Study: NCT03306602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtek Bulk Fill Posterior Restorative
Description: Filtek™ Bulk Fill Posterior Restorative is a one-step bulk placement solution for fast and easy posterior resin restorations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filtek Z350 XT
Description: Filtek Z350XT is a material for incremental layered composite resin restorations
Study: NCT02980367

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Management (Reconstruction)
Description: All surgical reconstructions will be patella tendon or hamstrings tendon depending on the surgeon's preference. All other care will be routine, including immediate post-operative care.
Study: NCT02499549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocamide diethanolamine
Description: 10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocamide diethanolamine
Description: 10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only
Study: NCT00325494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-009
Description: Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m\^2 up to 400 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-009
Description: Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m\^2 up to 400 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-009
Description: Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m\^2 up to 400 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-009
Description: Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m\^2 up to 400 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-009
Description: Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m\^2 up to 400 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-009
Description: Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m\^2 up to 400 mg/m\^2.
Study: NCT04387110

Intervention type: DRUG
Intervention: Ocrelizumab
Description: Receiving either 1infusion (600mg) or 2 infusions (300mg).
Study: NCT01325532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active CES
Description: CES current

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CES
Description: Sham CES (device off) for 20-minutes each day 5 days/week for 3 weeks.
Study: NCT00949390

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Survey given at appointment time, then dropped in specified box anonymously.
Study: NCT01558531

Intervention type: DEVICE
Intervention: DEB
Description: paclitaxel-eluting balloon angioplasty

Intervention type: DEVICE
Intervention: POBA
Description: conventional balloon angioplasty
Study: NCT03786510

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Control group received a personalized advice on lifestyle modification to prevent dementia and usual care of Community Center for Dementia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive + Maintenance program
Description: Both intensive and maintenance program~1. Intensive program The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching.~2. Maintenance program The allocated study assistants monthly check-up whether participants adhere to the altered habits or not, based on the workbook

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive program only
Description: Only the intensive program was conducted.~The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching.
Study: NCT00482287

Intervention type: DRUG
Group type: OTHER
Intervention: MTR105
Description: Intravenous administration, dose escalating (4 arms), single dose

Intervention type: DRUG
Group type: OTHER
Intervention: MTR105
Description: Intravenous administration, dose escalating (4 arms), single dose

Intervention type: DRUG
Group type: OTHER
Intervention: MTR105
Description: Intravenous administration, dose escalating (4 arms), single dose

Intervention type: DRUG
Group type: OTHER
Intervention: MTR105
Description: Intravenous administration, dose escalating (4 arms), single dose
Study: NCT03739359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasal cannula gas flow
Description: High flow nasal cannula (HFNC) is a relatively new oxygen device, which provides warmed and humidified oxygen for patients. When patients need to inhale aerosolized medication during HFNC, the nebulizer will be placed in-line in order to provide both treatments. This study will investigate the influence of three flow settings (50 L/min, GF:IF=1, GF:IF=0.5) on the clinical effects of nebulization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasal cannula gas flow
Description: High flow nasal cannula (HFNC) is a relatively new oxygen device, which provides warmed and humidified oxygen for patients. When patients need to inhale aerosolized medication during HFNC, the nebulizer will be placed in-line in order to provide both treatments. This study will investigate the influence of three flow settings (50 L/min, GF:IF=1, GF:IF=0.5) on the clinical effects of nebulization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nasal cannula gas flow
Description: High flow nasal cannula (HFNC) is a relatively new oxygen device, which provides warmed and humidified oxygen for patients. When patients need to inhale aerosolized medication during HFNC, the nebulizer will be placed in-line in order to provide both treatments. This study will investigate the influence of three flow settings (50 L/min, GF:IF=1, GF:IF=0.5) on the clinical effects of nebulization.
Study: NCT04122300

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of placebo is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
Study: NCT02284074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal LPS spray
Description: LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed. The dose per nostril corresponds to 1, 10, 30 and 100µg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Nasal LPS spray 1µg
Description: LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
Study: NCT01893242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aleglitazar
Description: Aleglitazar 150 mcg oral doses, once a day for approximately 3 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to aleglitazar, once a day for approximately 3 years
Study: NCT04039113

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT02740127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal Nerve Block (CNB)
Description: General anesthesia given in the OR using Propofol titrated for induction. CNB given as bolus injection into the caudal canal in the operating room (OR) by attending anesthesiologist using 1% Ropivacaine (max 5mg/kg) + 1:400,000 Epinephrine + Decadron 10 mg + Clonidine 100 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine 1 % (max 5mg/kg) by bolus injection given by anesthesiologist in OR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Epinephrine 1:400,000 by bolus injection given by anesthesiologist in OR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decadron
Description: Decadron 10 mg by bolus injection given by anesthesiologist in OR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 100 mcg by bolus injection given by anesthesiologist in OR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: General anesthesia given in the OR using Propofol titrated for induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General anesthesia given in the OR using Propofol titrated for induction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Study staff calls participant about 3 days after surgery to ask about their pain, amount of pain drugs they have taken, and how satisfied they are with the type of anesthesia and pain control they received. This call should last about 5-10 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone Call
Description: Study staff calls participant about 3 days after surgery to ask about their pain, amount of pain drugs they have taken, and how satisfied they are with the type of anesthesia and pain control they received. This call should last about 5-10 minutes.
Study: NCT01900990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation weaning
Description: We adopt Noninvasive Positive Pressure Ventilation in tracheotomy patients by capping the tracheotomy tube and deflating the cuff
Study: NCT03975348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow of warm and humidified oxygen/air mixture delivered through nasal cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow of warm and humidified oxygen/air mixture delivered through nasal cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow of warm and humidified oxygen/air mixture delivered through nasal cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow of warm and humidified oxygen/air mixture delivered through nasal cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow of warm and humidified oxygen/air mixture delivered through nasal cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow of warm and humidified oxygen/air mixture delivered through nasal cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow of warm and humidified oxygen/air mixture delivered through nasal cannula
Study: NCT00751569

Intervention type: OTHER
Intervention: blood donation
Description: obtaining cord blood
Study: NCT03378349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy
Description: The intervention lasts for 10 weeks and include: Education, Interoceptive exposure, exposure in-vivo, combining in-vivo exposure with interoceptive exposure, behavioral activation and relapse prevention. Include the guidance of a minimum weekly contact with a CBT psychologist.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Consist of standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health, without the guidance of a psychologist or any CBT interventions.
Study: NCT02009956

Intervention type: DEVICE
Group type: OTHER
Intervention: Subjects receiving DESyne Novolimus Eluting CSS
Study: NCT01484028

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A control lens (1DM)
Description: A marketed daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A control lens (1DM)
Description: A marketed daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A control lens (1DM)
Description: A marketed daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A control lens (1DM)
Description: A marketed daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with print and PVP for light eyes (EALE)
Description: A daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with print and PVP for light eyes (EALE)
Description: A daily disposable contact lens
Study: NCT02284074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Nasal LPS spray 10 µg
Description: LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Nasal LPS spray 30 µg
Description: LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Nasal LPS spray 100 µg
Description: LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
Study: NCT05306002

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Antioxidant therapy
Description: Antioxidant therapy based in the following dietary components: Zinc, Selenium, Magnesium, carotenoids, indole-3-carbinol, curcumin, epigalactocatechin, caffeine, resveratrol, lycopene, genistein, phytoestrogens
Study: NCT01484028

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with print and PVP for dark eyes (EADE)
Description: A daily disposable contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with print and PVP for dark eyes (EADE)
Description: A daily disposable contact lens
Study: NCT02413697

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two-dimensional ultrasound
Description: Two-dimensional ultrasound guided embryo transfer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three-dimensional ultrasound
Description: Three-dimensional ultrasound guided embryo transfer
Study: NCT03579147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with BTL EMSCULPT device
Description: The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
Study: NCT01140178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: Given IV
Study: NCT01347723

Intervention type: OTHER
Intervention: scrambler therapy
Description: Undergo scrambler therapy

Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT05207319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated Moral Reasoning Development Intervention (MRDI)
Description: The MRDI is comprised of 4 components that are run concurrently: moral reasoning, strategies of anger management and problem-solving and social skills.
Study: NCT03975348

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: Positive airway pressure applied through a sealed face mask

Intervention type: DEVICE
Group type: OTHER
Intervention: Facemask
Description: Oxygen therapy through a conventional facemask

Intervention type: DEVICE
Group type: OTHER
Intervention: Facemask
Description: Oxygen therapy through a conventional facemask
Study: NCT01159938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro
Description: Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro
Description: Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.
Study: NCT03477448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: an antibiotic derived from Streptomyces verticillus, has an antitumor, antibacterial, and antiviral activity that may be related to its ability to bind with DNA, causing bleomycin strand scission and elimination of pyrimidine and purine bases. The bleomycin hydrolase enzyme, which is known to inactivate bleomycin, is normally found in all body tissues but is present in very small amounts in skin .~* Intra-lesional bleomycin injection (IBI) has been used for the treatment of warts.
Study: NCT01967888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiologic solution administered at 0.25 mL/kg/hour
Study: NCT00408876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Study: NCT01347723

Intervention type: PROCEDURE
Intervention: management of therapy complications
Description: Undergo scrambler therapy
Study: NCT00287040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored, interactive intervention for mammography screening
Description: Follow ups will occur at 6-, 12-, and 21-months in order to determine effectiveness of intervention as well as cost effectiveness and variation based on participant characteristics to facilitate a more effective program for mammography screenings

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored, interactive intervention for mammography screening
Description: Follow ups will occur at 6-, 12-, and 21-months in order to determine effectiveness of intervention as well as cost effectiveness and variation based on participant characteristics to facilitate a more effective program for mammography screenings
Study: NCT02538575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Description: a walk of 6 minutes repeated twice in an interval of 30 minutes
Study: NCT04712162

Intervention type: OTHER
Group type: OTHER
Intervention: Other
Description: Compare time to awakening and quality of recovery after general anesthesia between two groups.

Intervention type: OTHER
Group type: OTHER
Intervention: Other
Description: Compare time to awakening and quality of recovery after general anesthesia between two groups.
Study: NCT04566614

Intervention type: OTHER
Intervention: ctDNA blood sampling
Description: Screening/baseline blood sample to be analysed for ctDNA

Intervention type: OTHER
Intervention: ctDNA blood sampling
Description: Screening/baseline blood sample to be analysed for ctDNA

Intervention type: OTHER
Intervention: ctDNA blood sampling
Description: Screening/baseline blood sample to be analysed for ctDNA

Intervention type: OTHER
Intervention: ctDNA blood sampling
Description: Screening/baseline blood sample to be analysed for ctDNA

Intervention type: OTHER
Intervention: ctDNA blood sampling
Description: Screening/baseline blood sample to be analysed for ctDNA

Intervention type: OTHER
Intervention: ctDNA blood sampling
Description: Screening/baseline blood sample to be analysed for ctDNA